Following are the materials presented at the Long-Term Follow Up workshop held in Minneapolis, Minnesota. To access the slides or other materials which were presented at the workshop, simply click on a specific part of the agenda. If there were no slides or materials available during a portion of the program, there will not be a link.
This workshop on long-term follow up of participants in human gene transfer research was co-sponsored by the American Society of Gene Therapy, the Center for Biologics Evaluation & Research, (CBER/FDA), the Office of Biotechnology Activities, (OBA/NIH), Biotechnology Industry Organization (BIO), and Pharmaceutical Research and Manufacturers of America (PhRMA).
Audience
The target audience for this workshop included all individuals involved in the conduct or oversight of gene therapy clinical trials, such as:
Purpose of the Workshop
To discuss the scientific, clinical, ethical, social and legal issues related to the long-term follow up of patients who participate in gene therapy clinical trials
Goals
Organizing Committee
Philippe C. Bishop, MD, Sarah Carr, Barrie J. Carter, PhD, John Cutt, PhD, Michael Egan, Terence Flotte, MD, Mark Frankel, PhD, Beth Hutchins, PhD, Richard A. Knazek, MD, Donald B. Kohn, MD, Alex Kuta, PhD, Bob Martin, Manal Morsey, MD, PhD, MBA, Susan P. Nemeth, PhD, Philip D. Noguchi, MD, Amy Patterson, MD, Sara Radcliffe, Alex Rakowsky, MD, Cynthia Rask, Stephen Rose, PhD, Stephanie L. Simek, PhD, Melissa Tice, Alice E. Till, PhD, Marie A. Vodicka, PhD, Carolyn A. Wilson, PhD
Day One (June 1, 2004)
Long Term Follow Up: Overview of Current Requirements and Workshop Goals
Stephanie Simek, PhD
FDA/CBER/OTRR
Long-Term Follow-Up in Bone Marrow Transplantation
Mary Horowitz, MD, MS
Scientific Director, International Bone Marrow Registry/Allogeneic Bone Marrow Registry, Robert A Uihlein Professor of Medicine, Medical College of Wisconsin
Use of the Gaucher Registry to Track Outcomes
Neal Mantick
Director, Global Registry Programs, Genzyme
Barrie J. Carter, PhD, Targeted Genetics Corporation &
Carolyn Wilson, PhD, FDA/CBER
Terence R. Flotte, MD, University of Florida
Daniel Rosenblum, MD, FDA/CBER
Scientific Issues Breakout Sessions
Co-Moderators Session 1:
Barrie J. Carter, PhD, Targeted Genetics Corporation
Stephanie Simek, PhD, FDA/CBER/OTRRCo-Moderators Session 2:
Beth Hutchins, PhD, Canji, Inc.
Carolyn Wilson, PhD, FDA/CBER
Clinical Issues Breakout Sessions
Co-Moderators Session 1:
Stephen Rose, PhD, OBA/NIH
Daniel Rosenblum, MD, FDA/CBERCo-Moderators Session 2:
Terence R. Flotte, MD, University of Florida
Philip Noguchi, MD, FDA/CBER
Legal / Social / Ethical Issues Breakout Session
Legal Issues Co-Moderators:
Lewis A. Grossman, JD
Professor of Law, Washington College of Law, American University
Of Counsel, Covington & BurlingPrivacy Issues in Long-Term Follow Up
Hilary Schock, JD, MBA
Merck & Co., IncEthics & Social Issues Co-Moderators:
William L. Allen, JD
Associate Professor & Director, Bioethics Program, CHFM, University of FloridaEthical and Social Issues
James F. Childress, PhD
Kyle Professor of Religious Studies, Professor of Medical Education
University of VirginiaHIPAA Privacy Rule and Long-Term Follow-up in Research
Lora Kutkat, MS
Office of Science, Policy, Office of the Director, NIH
Long Term Animal Models Issues Breakout Session
Co-Moderators:
Theresa Chen, PhD
Pharm/Tox Branch, FDA/CBER/OCTGT
Cynthia Dunbar, MD
Head, Molecular Hematopoiesis Section, Hematology Branch, NHLBI, NIH
Day Two (June 2, 2004)
Reports from all Breakout Sessions
What Information Would Bring About a Reassessment of the Requirements for Long-Term Follow Up in a Particular Class of Human Gene Transfer Clinical Trials?
Co-moderators:
Barrie J. Carter, PhD, Targeted Genetics Corporation
Terence R. Flotte, MD, University of Florida
Daniel Rosenblum, MD, FDA/CBER
Carolyn Wilson, PhD, FDA/CBER
Concluding Remarks
Stephanie Simek, PhD, FDA/CBER/OTRR